1. Home
  2. TBBK vs NVAX Comparison

TBBK vs NVAX Comparison

Compare TBBK & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo The Bancorp Inc

TBBK

The Bancorp Inc

HOLD

Current Price

$70.21

Market Cap

3.1B

Sector

Finance

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$7.33

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TBBK
NVAX
Founded
1999
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
1.1B
IPO Year
2004
1995

Fundamental Metrics

Financial Performance
Metric
TBBK
NVAX
Price
$70.21
$7.33
Analyst Decision
Buy
Hold
Analyst Count
3
8
Target Price
$69.33
$9.75
AVG Volume (30 Days)
659.5K
3.4M
Earning Date
01-29-2026
02-26-2026
Dividend Yield
N/A
N/A
EPS Growth
21.10
N/A
EPS
4.78
2.07
Revenue
$523,163,000.00
$1,064,651,000.00
Revenue This Year
N/A
$58.91
Revenue Next Year
$7.37
N/A
P/E Ratio
$14.51
$3.68
Revenue Growth
10.84
20.27
52 Week Low
$40.51
$5.01
52 Week High
$81.65
$11.55

Technical Indicators

Market Signals
Indicator
TBBK
NVAX
Relative Strength Index (RSI) 59.59 59.18
Support Level $67.95 $6.60
Resistance Level $70.56 $7.76
Average True Range (ATR) 1.79 0.24
MACD 0.01 0.11
Stochastic Oscillator 69.02 67.19

Price Performance

Historical Comparison
TBBK
NVAX

About TBBK The Bancorp Inc

The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, specialty finance (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Specialty finance includes REBL (real estate bridge lending) comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: